Our findings illustrated that Notch3 signaling activation is necessary for the development of the mammary gland, but its hyperactivation closely relates to breast cancer progression, and that Notch3-regulating CCL2/CCR4 axis should be the target for breast cancer therapy. The gene discussed is CCL2; the disease is breast carcinoma.